The expanding role of prodrugs in contemporary drug design and development

[1]  Martin D. Eastgate,et al.  Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir. , 2018, Journal of medicinal chemistry.

[2]  J. Rautio,et al.  Prodrugs – Recent approvals and a glimpse of the pipeline , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[3]  Q. You,et al.  Prodrug strategy for cancer cell-specific targeting: A recent overview. , 2017, European journal of medicinal chemistry.

[4]  M. Wendt,et al.  Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection. , 2017, Journal of medicinal chemistry.

[5]  Sur Sharma,et al.  Antibody Directed Enzyme Prodrug Therapy (ADEPT): Trials and tribulations , 2017, Advanced drug delivery reviews.

[6]  G. Tiram,et al.  Two-step polymer- and liposome-enzyme prodrug therapies for cancer: PDEPT and PELT concepts and future perspectives. , 2017, Advanced drug delivery reviews.

[7]  A. Zelikin,et al.  Recent advances in macromolecular prodrugs , 2017 .

[8]  L. Di.  Reaction phenotyping to assess victim drug-drug interaction risks , 2017, Expert opinion on drug discovery.

[9]  J. Balzarini,et al.  The ProTide Prodrug Technology: From the Concept to the Clinic , 2017, Journal of medicinal chemistry.

[10]  K. Rahbar,et al.  177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  D. Grigoriadis,et al.  Pharmacologic Characterization of Valbenazine (NBI-98854) and Its Metabolites , 2017, The Journal of Pharmacology and Experimental Therapeutics.

[12]  T. Maurer,et al.  In Vitro-In Vivo Extrapolation of Intestinal Availability for Carboxylesterase Substrates Using Portal Vein-Cannulated Monkey. , 2017, Journal of pharmaceutical sciences.

[13]  L. Scott.  Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma , 2017, Drugs.

[14]  Sur Sharma,et al.  Translating antibody directed enzyme prodrug therapy (ADEPT) and prospects for combination , 2017, Expert opinion on biological therapy.

[15]  E. Clercq,et al.  Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF). , 2016, Biochemical pharmacology.

[16]  S. Mosaed,et al.  Critical evaluation of latanoprostene bunod in the treatment of glaucoma , 2016, Clinical ophthalmology.

[17]  Y. Mehellou,et al.  Nucleoside Phosphate and Phosphonate Prodrug Clinical Candidates. , 2016, Journal of medicinal chemistry.

[18]  Tommy Liljefors,et al.  Textbook of drug design and discovery , 2016 .

[19]  B. Reigner,et al.  A Physiologically Based Pharmacokinetic Model for Ganciclovir and Its Prodrug Valganciclovir in Adults and Children , 2016, The AAPS Journal.

[20]  R. Limberger,et al.  Lisdexamfetamine: A pharmacokinetic review. , 2016, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[21]  R. Linker,et al.  Dimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapy , 2016, Therapeutic advances in chronic disease.

[22]  B. Faller,et al.  Evaluation of the GastroPlus™ Advanced Compartmental and Transit (ACAT) Model in Early Discovery , 2016, Pharmaceutical Research.

[23]  Chwan-Fwu Lin,et al.  The codrug approach for facilitating drug delivery and bioactivity , 2016, Expert opinion on drug delivery.

[24]  Lisa A. Raedler.  Aripiprazole Lauroxil (Aristada): Long-Acting Atypical Antipsychotic Injection Approved for the Treatment of Patients with Schizophrenia. , 2016, American health & drug benefits.

[25]  Nicholas A Meanwell,et al.  Improving Drug Design: An Update on Recent Applications of Efficiency Metrics, Strategies for Replacing Problematic Elements, and Compounds in Nontraditional Drug Space. , 2016, Chemical research in toxicology.

[26]  William A. Lee,et al.  Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys , 2016, Nature.

[27]  L. Scott.  Selexipag: First Global Approval , 2016, Drugs.

[28]  P. Loadman,et al.  Proteases in cancer drug delivery. , 2016, Advanced drug delivery reviews.

[29]  P. Polakis.  Antibody Drug Conjugates for Cancer Therapy , 2016, Pharmacological Reviews.

[30]  S. Yant,et al.  Intracellular Activation of Tenofovir Alafenamide and the Effect of Viral and Host Protease Inhibitors , 2015, Antimicrobial Agents and Chemotherapy.

[31]  Sheridan M. Hoy.  Tafluprost/Timolol: A Review in Open-Angle Glaucoma or Ocular Hypertension , 2015, Drugs.

[32]  M. Clozel,et al.  Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension. , 2015, Journal of medicinal chemistry.

[33]  Brent R. Martin,et al.  Substrate-Competitive Activity-Based Profiling of Ester Prodrug Activating Enzymes. , 2015, Molecular pharmaceutics.

[34]  S. Factor,et al.  NBI‐98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double‐blind, placebo‐controlled study , 2015, Movement disorders : official journal of the Movement Disorder Society.

[35]  D. Neri,et al.  Antibody-Drug Conjugates and Small Molecule-Drug Conjugates: Opportunities and Challenges for the Development of Selective Anticancer Cytotoxic Agents. , 2015, Journal of medicinal chemistry.

[36]  G. Wang,et al.  CES1 genetic variation affects the activation of angiotensin-converting enzyme inhibitors , 2015, The Pharmacogenomics Journal.

[37]  I. Floriani,et al.  Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure , 2015, Clinical ophthalmology.

[38]  N. Djebli,et al.  Physiologically Based Pharmacokinetic Modeling for Sequential Metabolism: Effect of CYP2C19 Genetic Polymorphism on Clopidogrel and Clopidogrel Active Metabolite Pharmacokinetics , 2015, Drug Metabolism and Disposition.

[39]  A. Mathias,et al.  Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir , 2015, Clinical Pharmacokinetics.

[40]  P. Low,et al.  Principles in the design of ligand-targeted cancer therapeutics and imaging agents , 2015, Nature Reviews Drug Discovery.

[41]  J. Tack,et al.  Rapid conversion of the ester prodrug abiraterone acetate results in intestinal supersaturation and enhanced absorption of abiraterone: in vitro, rat in situ and human in vivo studies. , 2015, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[42]  S. Yamashita,et al.  Quantitative Assessment of Intestinal First-pass Metabolism of Oral Drugs Using Portal-vein Cannulated Rats , 2015, Pharmaceutical Research.

[43]  S. Owen,et al.  Antibody Drug Conjugates: Design and Selection of Linker, Payload and Conjugation Chemistry , 2015, The AAPS Journal.

[44]  J. Dingemanse,et al.  Multiple-Dose Up-Titration Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Selexipag, an Orally Available Selective Prostacyclin Receptor Agonist, in Healthy Subjects , 2014, Pharmacology.

[45]  Peter Timmins,et al.  Enabled clinical use of an HIV-1 attachment inhibitor through drug delivery. , 2014, Drug discovery today.

[46]  Aleksandra Galetin,et al.  Hepatic, Intestinal, Renal, and Plasma Hydrolysis of Prodrugs in Human, Cynomolgus Monkey, Dog, and Rat: Implications for In Vitro–In Vivo Extrapolation of Clearance of Prodrugs , 2014, Drug Metabolism and Disposition.

[47]  R. Schinazi,et al.  Synthesis of Nucleoside Phosphate and Phosphonate Prodrugs , 2014, Chemical reviews.

[48]  Andrea N Edginton,et al.  Physiologically Based Pharmacokinetic Modeling of Impaired Carboxylesterase-1 Activity: Effects on Oseltamivir Disposition , 2014, Clinical Pharmacokinetics.

[49]  R. Holm,et al.  Biological conversion of aripiprazole lauroxil - An N-acyloxymethyl aripiprazole prodrug , 2014, Results in pharma sciences.

[50]  U. Weidle,et al.  Proteases as activators for cytotoxic prodrugs in antitumor therapy. , 2014, Cancer genomics & proteomics.

[51]  M. Mason,et al.  Application of ProTide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development. , 2014, Journal of medicinal chemistry.

[52]  R. B. Parker,et al.  Identification of Carboxylesterase-Dependent Dabigatran Etexilate Hydrolysis , 2014, Drug Metabolism and Disposition.

[53]  T. Ryan,et al.  Randomized phase 2 study of pegylated SN‐38 (EZN‐2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer , 2013, Cancer.

[54]  R. Burger,et al.  PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  M. Brandsch.  Drug transport via the intestinal peptide transporter PepT1. , 2013, Current opinion in pharmacology.

[56]  B. Vig,et al.  Amino acids as promoieties in prodrug design and development. , 2013, Advanced drug delivery reviews.

[57]  B. Ploeger,et al.  Predicting human exposure of active drug after oral prodrug administration, using a joined in vitro/in silico-in vivo extrapolation and physiologically-based pharmacokinetic modeling approach. , 2013, Journal of pharmacological and toxicological methods.

[58]  P. Ruzza,et al.  Glutathione Transferase (GST)-Activated Prodrugs , 2013, Pharmaceutics.

[59]  V. Herring,et al.  The Role of Human Carboxylesterases in Drug Metabolism: Have We Overlooked Their Importance? , 2013, Pharmacotherapy.

[60]  P. Ortiz de Montellano.  Cytochrome P450-activated prodrugs. , 2013, Future medicinal chemistry.

[61]  J. Sukbuntherng,et al.  Population Pharmacokinetics and Pharmacodynamics of Gabapentin After Administration of Gabapentin Enacarbil , 2013, Journal of clinical pharmacology.

[62]  Hywel D Williams,et al.  Strategies to Address Low Drug Solubility in Discovery and Development , 2013, Pharmacological Reviews.

[63]  H. Nar,et al.  The Discovery of Dabigatran Etexilate , 2012, Front. Pharmacol..

[64]  M. Krystal,et al.  Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects. , 2012, The Journal of infectious diseases.

[65]  Kayoko Ohura,et al.  Species difference of esterase expression and hydrolase activity in plasma. , 2012, Journal of pharmaceutical sciences.

[66]  G. Ecker,et al.  Evidence-based approach to assess passive diffusion and carrier-mediated drug transport. , 2012, Drug discovery today.

[67]  J. Fromm,et al.  Clinical binding properties, internalization kinetics, and clinicopathologic activity of brentuximab vedotin: an antibody-drug conjugate for CD30-positive lymphoid neoplasms. , 2012, Clinical lymphoma, myeloma & leukemia.

[68]  H. Maag.  Overcoming poor permeability - the role of prodrugs for oral drug delivery. , 2012, Drug discovery today. Technologies.

[69]  S. Banerjee,et al.  Poly(ethylene glycol)-Prodrug Conjugates: Concept, Design, and Applications , 2012, Journal of drug delivery.

[70]  Li Di,et al.  Bridging solubility between drug discovery and development. , 2012, Drug discovery today.

[71]  Mark D. Johnson,et al.  Use of enzyme inhibitors to evaluate the conversion pathways of ester and amide prodrugs: a case study example with the prodrug ceftobiprole medocaril. , 2012, Journal of pharmaceutical sciences.

[72]  T. Kurtz,et al.  Differential pharmacology and benefit/risk of azilsartan compared to other sartans , 2012, Vascular health and risk management.

[73]  N. Meanwell,et al.  Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment 6. Preclinical and human pharmacokinetic profiling of BMS-663749, a phosphonooxymethyl prodrug of the HIV-1 attachment inhibitor 2-(4-benzoyl-1-piperazinyl)-1-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)-2-oxoethanone (BMS-488043) , 2012, Journal of medicinal chemistry.

[74]  Harvey J. Clewell,et al.  A Semiphysiologically Based Pharmacokinetic Modeling Approach to Predict the Dose-Exposure Relationship of an Antiparasitic Prodrug/Active Metabolite Pair , 2012, Drug Metabolism and Disposition.

[75]  S. Wrighton,et al.  Characterization of the Expression and Activity of Carboxylesterases 1 and 2 from the Beagle Dog, Cynomolgus Monkey, and Human , 2011, Drug Metabolism and Disposition.

[76]  B. Hall,et al.  Activation of Benznidazole by Trypanosomal Type I Nitroreductases Results in Glyoxal Formation , 2011, Antimicrobial Agents and Chemotherapy.

[77]  R. Duncan,et al.  Nanomedicine(s) under the microscope. , 2011, Molecular pharmaceutics.

[78]  Longqin Hu,et al.  Enzyme-mediated hydrolytic activation of prodrugs , 2011 .

[79]  Hannu Raunio,et al.  Prodrugs—from Serendipity to Rational Design , 2011, Pharmacological Reviews.

[80]  S. Dhaneshwar,et al.  Rational design and development of colon-specific prodrugs. , 2011, Current topics in medicinal chemistry.

[81]  Kai Hung Tiong,et al.  CYP2S1 and CYP2W1 Mediate 2-(3,4-Dimethoxyphenyl)-5-Fluorobenzothiazole (GW-610, NSC 721648) Sensitivity in Breast and Colorectal Cancer Cells , 2011, Molecular Cancer Therapeutics.

[82]  M. Otto,et al.  Activity and the metabolic activation pathway of the potent and selective hepatitis C virus pronucleotide inhibitor PSI-353661. , 2011, Antiviral research.

[83]  R. Duncan.  Polymer therapeutics as nanomedicines: new perspectives. , 2011, Current opinion in biotechnology.

[84]  B. Hall,et al.  Trypanocidal activity of nitroaromatic prodrugs: current treatments and future perspectives. , 2011, Current topics in medicinal chemistry.

[85]  N. Meanwell.  Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety. , 2011, Chemical research in toxicology.

[86]  Nicholas H Oberlies,et al.  Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma , 2011, The Journal of Antibiotics.

[87]  J. Rautio,et al.  Prodrugs Designed to Target Transporters for Oral Drug Delivery , 2011 .

[88]  C. Springer,et al.  Directed Enzyme Prodrug Therapies , 2011 .

[89]  Victor R. Guarino.  Modulating Solubility Through Prodrugs for Oral and IV Drug Delivery , 2011 .

[90]  V. Stella.  Prodrugs: Some thoughts and current issues. , 2010, Journal of pharmaceutical sciences.

[91]  Kayoko Ohura,et al.  The role of intestinal carboxylesterase in the oral absorption of prodrugs. , 2010, Current drug metabolism.

[92]  S. Mandlekar,et al.  Prodrug design to improve pharmacokinetic and drug delivery properties: challenges to the discovery scientists. , 2010, Current medicinal chemistry.

[93]  M. Otto,et al.  Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. , 2010, Journal of medicinal chemistry.

[94]  M. Otto,et al.  Mechanism of Activation of PSI-7851 and Its Diastereoisomer PSI-7977 , 2010, The Journal of Biological Chemistry.

[95]  Li Di,et al.  Coexistence of passive and carrier-mediated processes in drug transport , 2010, Nature Reviews Drug Discovery.

[96]  M. Goldberg,et al.  Role of clevidipine butyrate in the treatment of acute hypertension in the critical care setting: a review , 2010, Vascular health and risk management.

[97]  M. Pennick.  Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine , 2010, Neuropsychiatric disease and treatment.

[98]  M. Otto,et al.  PSI-7851, a Pronucleotide of β-d-2′-Deoxy-2′-Fluoro-2′-C-Methyluridine Monophosphate, Is a Potent and Pan-Genotype Inhibitor of Hepatitis C Virus Replication , 2010, Antimicrobial Agents and Chemotherapy.

[99]  A. Narang,et al.  Targeted Delivery of Small and Macromolecular Drugs , 2010 .

[100]  M. Erion.  Site-Specific Prodrug Activation Strategies for Targeted Drug Action , 2010 .

[101]  E. Ben-Menachem.  Eslicarbazepine Acetate: A Well-Kept Secret? , 2010, Epilepsy currents.

[102]  J. Balzarini,et al.  Aryloxy Phosphoramidate Triesters: a Technology for Delivering Monophosphorylated Nucleosides and Sugars into Cells , 2009, ChemMedChem.

[103]  P. Dobesh.  Pharmacokinetics and Pharmacodynamics of Prasugrel, a Thienopyridine P2Y12 Inhibitor , 2009, Pharmacotherapy.

[104]  J. Sukbuntherng,et al.  Pharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: a randomized-sequence, double-blind, placebo-controlled crossover study in healthy volunteers. , 2009, Clinical therapeutics.

[105]  Y. Fukano,et al.  Disposition and Metabolism of a Novel Prostanoid Antiglaucoma Medication, Tafluprost, Following Ocular Administration to Rats , 2009, Drug Metabolism and Disposition.

[106]  Y. Lai,et al.  Evaluation of in Vitro Models for Screening Alkaline Phosphatase-Mediated Bioconversion of Phosphate Ester Prodrugs , 2009, Drug Metabolism and Disposition.

[107]  D. Kerr,et al.  Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. , 2009, International journal of oncology.

[108]  Sebastian Polak,et al.  Population-Based Mechanistic Prediction of Oral Drug Absorption , 2009, The AAPS Journal.

[109]  V. Stella,et al.  Your prodrug releases formaldehyde: should you be concerned? No! , 2008, Journal of pharmaceutical sciences.

[110]  J. Rautio,et al.  Cytochrome P450-activated prodrugs: targeted drug delivery. , 2008, Current medicinal chemistry.

[111]  J. Leppänen,et al.  Synthesis, in vitro and in vivo characterization of novel ethyl dioxy phosphate prodrug of propofol. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[112]  M. Socinski,et al.  Randomized Phase III Trial Comparing Single-Agent Paclitaxel Poliglumex (CT-2103, PPX) with Single-Agent Gemcitabine or Vinorelbine for the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[113]  M. Michel.  Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome , 2008, Expert opinion on pharmacotherapy.

[114]  Alan G. E. Wilson,et al.  Discovery and Characterization of Novel Tryptophan Hydroxylase Inhibitors That Selectively Inhibit Serotonin Synthesis in the Gastrointestinal Tract , 2008, Journal of Pharmacology and Experimental Therapeutics.

[115]  Tycho Heimbach,et al.  Prodrugs: design and clinical applications , 2008, Nature Reviews Drug Discovery.

[116]  J. M. Clancy,et al.  Prodrugs for Amines , 2008, Molecules.

[117]  L. Di,et al.  Drug-like Properties: Concepts, Structure Design and Methods: from ADME to Toxicity Optimization , 2008 .

[118]  Masakiyo Hosokawa,et al.  Structure and Catalytic Properties of Carboxylesterase Isozymes Involved in Metabolic Activation of Prodrugs , 2008, Molecules.

[119]  F. Kratz,et al.  Prodrug Strategies in Anticancer Chemotherapy , 2008, ChemMedChem.

[120]  T. Asaki,et al.  Synthesis and evaluation of N-acylsulfonamide and N-acylsulfonylurea prodrugs of a prostacyclin receptor agonist. , 2007, Bioorganic & medicinal chemistry.

[121]  E. Perkins,et al.  Pharmacokinetics, Metabolism, and Excretion of the Intestinal Peptide Transporter 1 (SLC15A1)-Targeted Prodrug (1S,2S,5R,6S)-2-[(2′S)-(2-Amino)propionyl]aminobicyclo[3.1.0.]hexen-2,6-dicarboxylic acid (LY544344) in Rats and Dogs: Assessment of First-Pass Bioactivation and Dose Linearity , 2007, Drug Metabolism and Disposition.

[122]  K. Adachi,et al.  FTY720 Story. Its Discovery and the Following Accelerated Development of Sphingosine 1-Phosphate Receptor Agonists as Immunomodulators Based on Reverse Pharmacology , 2007, Perspectives in medicinal chemistry.

[123]  R. Danesi,et al.  CYP2D6 polymorphisms and the impact on tamoxifen therapy. , 2007, Journal of pharmaceutical sciences.

[124]  K. Rathgen,et al.  The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. , 2007, British journal of clinical pharmacology.

[125]  H. Tillmann.  Pradefovir, a liver-targeted prodrug of adefovir against HBV infection. , 2007, Current opinion in investigational drugs.

[126]  V. Stella,et al.  Prodrug strategies to overcome poor water solubility. , 2007, Advanced drug delivery reviews.

[127]  Rachelle S. Singleton,et al.  Mechanism of Action and Preclinical Antitumor Activity of the Novel Hypoxia-Activated DNA Cross-Linking Agent PR-104 , 2007, Clinical Cancer Research.

[128]  Robert T. Taylor,et al.  A Novel Promoter Element Containing Multiple Overlapping Xenobiotic and Hypoxia Response Elements Mediates Induction of Cytochrome P4502S1 by Both Dioxin and Hypoxia* , 2007, Journal of Biological Chemistry.

[129]  Scott A. Shaffer,et al.  In vitro and in vivo metabolism of paclitaxel poliglumex: identification of metabolites and active proteases , 2007, Cancer Chemotherapy and Pharmacology.

[130]  F. Akhlaghi,et al.  Anti-Influenza Prodrug Oseltamivir Is Activated by Carboxylesterase Human Carboxylesterase 1, and the Activation Is Inhibited by Antiplatelet Agent Clopidogrel , 2006, Journal of Pharmacology and Experimental Therapeutics.

[131]  D. Goldstein,et al.  L-Dihydroxyphenylserine (L-DOPS): a norepinephrine prodrug. , 2006, Cardiovascular drug reviews.

[132]  Ruth Duncan,et al.  Polymer conjugates as anticancer nanomedicines , 2006, Nature Reviews Cancer.

[133]  J. Ocampo-Candiani,et al.  In Vitro Activities of DA-7157 and DA-7218 against Mycobacterium tuberculosis and Nocardia brasiliensis , 2006, Antimicrobial Agents and Chemotherapy.

[134]  N. Fujii,et al.  Transport Characteristics of a Novel Peptide Transporter 1 Substrate, Antihypotensive Drug Midodrine, and Its Amino Acid Derivatives , 2006, Journal of Pharmacology and Experimental Therapeutics.

[135]  M. Ingelman-Sundberg,et al.  Tumor-specific expression of the novel cytochrome P450 enzyme, CYP2W1. , 2006, Biochemical and biophysical research communications.

[136]  M. Erion,et al.  HepDirect prodrugs for targeting nucleotide-based antiviral drugs to the liver. , 2006, Current opinion in investigational drugs.

[137]  A. Schmitt-Hoffmann,et al.  Multiple-Dose Pharmacokinetics and Safety of the New Antifungal Triazole BAL4815 after Intravenous Infusion and Oral Administration of Its Prodrug, BAL8557, in Healthy Volunteers , 2006, Antimicrobial Agents and Chemotherapy.

[138]  C. Beglinger,et al.  Single-Ascending-Dose Pharmacokinetics and Safety of the Novel Broad-Spectrum Antifungal Triazole BAL4815 after Intravenous Infusions (50, 100, and 200 Milligrams) and Oral Administrations (100, 200, and 400 Milligrams) of Its Prodrug, BAL8557, in Healthy Volunteers , 2006, Antimicrobial Agents and Chemotherapy.

[139]  E. Duysen,et al.  Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. , 2005, Biochemical pharmacology.

[140]  Graeme I Murray,et al.  Profiling Cytochrome P450 Expression in Ovarian Cancer: Identification of Prognostic Markers , 2005, Clinical Cancer Research.

[141]  M. Clay,et al.  Dipeptides as effective prodrugs of the unnatural amino acid (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740), a selective group II metabotropic glutamate receptor agonist. , 2005, Journal of medicinal chemistry.

[142]  R. Ueda,et al.  Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5′-deoxy-5-fluorouridine (5′-DFUR) , 2005, Cancer Chemotherapy and Pharmacology.

[143]  M. Erion,et al.  Liver-Targeted Drug Delivery Using HepDirect1 Prodrugs , 2005, Journal of Pharmacology and Experimental Therapeutics.

[144]  M. Linenberger,et al.  CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance , 2005, Leukemia.

[145]  E. Sausville,et al.  FLUORINATED 2-(4-AMINO-3-METHYLPHENYL)BENZOTHIAZOLES INDUCE CYP1A1 EXPRESSION, BECOME METABOLIZED, AND BIND TO MACROMOLECULES IN SENSITIVE HUMAN CANCER CELLS , 2004, Drug Metabolism and Disposition.

[146]  R. Barrett,et al.  XP13512 [(±)-1-([(α-Isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane Acetic Acid], A Novel Gabapentin Prodrug: I. Design, Synthesis, Enzymatic Conversion to Gabapentin, and Transport by Intestinal Solute Transporters , 2004, Journal of Pharmacology and Experimental Therapeutics.

[147]  R. Barrett,et al.  XP13512 [(±)-1-([(α-Isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane Acetic Acid], A Novel Gabapentin Prodrug: II. Improved Oral Bioavailability, Dose Proportionality, and Colonic Absorption Compared with Gabapentin in Rats and Monkeys , 2004, Journal of Pharmacology and Experimental Therapeutics.

[148]  J. Schellens,et al.  A Phase I and Pharmacological Study of the Platinum Polymer AP5280 Given as an Intravenous Infusion Once Every 3 Weeks in Patients with Solid Tumors , 2004, Clinical Cancer Research.

[149]  B. Testa,et al.  Lessons learned from marketed and investigational prodrugs. , 2004, Journal of medicinal chemistry.

[150]  Sara K Quinney,et al.  Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[151]  M. Erion,et al.  Design, synthesis, and characterization of a series of cytochrome P(450) 3A-activated prodrugs (HepDirect prodrugs) useful for targeting phosph(on)ate-based drugs to the liver. , 2004, Journal of the American Chemical Society.

[152]  E. Furfine,et al.  Preclinical Pharmacology and Pharmacokinetics of GW433908, a Water-Soluble Prodrug of the Human Immunodeficiency Virus Protease Inhibitor Amprenavir , 2004, Antimicrobial Agents and Chemotherapy.

[153]  V. Ganapathy,et al.  Transport of Amino Acid-Based Prodrugs by the Na+- and Cl--Coupled Amino Acid Transporter ATB0,+ and Expression of the Transporter in Tissues Amenable for Drug Delivery , 2004, Journal of Pharmacology and Experimental Therapeutics.

[154]  Keith Tan,et al.  Pharmacokinetics and Safety of Fosfluconazole after Single Intravenous Bolus Injection in Healthy Male Japanese Volunteers , 2004, Journal of clinical pharmacology.

[155]  Nico P E Vermeulen,et al.  Enzyme-Catalyzed Activation of Anticancer Prodrugs , 2004, Pharmacological Reviews.

[156]  V. Stella.  Prodrugs as therapeutics , 2004 .

[157]  N. Minton.  Clostridia in cancer therapy , 2003, Nature Reviews Microbiology.

[158]  K. Beaumont,et al.  Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist. , 2003, Current drug metabolism.

[159]  Damon L. Meyer,et al.  cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. , 2003, Blood.

[160]  N. Rodríguez-Hornedo,et al.  Enzyme-mediated precipitation of parent drugs from their phosphate prodrugs. , 2003, International journal of pharmaceutics.

[161]  J. Davies,et al.  PDEPT: polymer-directed enzyme prodrug therapy. 2. HPMA copolymer-beta-lactamase and HPMA copolymer-C-Dox as a model combination. , 2003, Bioconjugate chemistry.

[162]  G. Flynn,et al.  Absorption Rate Limit Considerations for Oral Phosphate Prodrugs , 2003, Pharmaceutical Research.

[163]  Damon L. Meyer,et al.  Development of potent monoclonal antibody auristatin conjugates for cancer therapy , 2003, Nature Biotechnology.

[164]  Y. Ikeda,et al.  TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties. , 2003, Bioorganic & medicinal chemistry.

[165]  P. Wang,et al.  Glucuronides in anti-cancer therapy. , 2003, Current medicinal chemistry. Anti-cancer agents.

[166]  Richard B Greenwald,et al.  Effective drug delivery by PEGylated drug conjugates. , 2003, Advanced drug delivery reviews.

[167]  M. Sakaitani,et al.  Design, synthesis and antifungal activity of a novel water soluble prodrug of antifungal triazole. , 2003, Bioorganic & medicinal chemistry letters.

[168]  E. Brass.  Pivalate-Generating Prodrugs and Carnitine Homeostasis in Man , 2002, Pharmacological Reviews.

[169]  D. Rognan,et al.  Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound. , 2002, Journal of medicinal chemistry.

[170]  C. Springer,et al.  A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours , 2002, British Journal of Cancer.

[171]  W. Prince,et al.  Pharmacokinetics of GW433908, a Prodrug of Amprenavir, in Healthy Male Volunteers , 2002, Journal of clinical pharmacology.

[172]  H. Nar,et al.  Structure-based design of novel potent nonpeptide thrombin inhibitors. , 2002, Journal of medicinal chemistry.

[173]  M. Butters,et al.  The Discovery and Process Development of a Commercial Route to the Water Soluble Prodrug, Fosfluconazole , 2002 .

[174]  F. Aoki,et al.  Oseltamivir: a clinical and pharmacological perspective , 2001, Expert opinion on pharmacotherapy.

[175]  A. Photiou,et al.  Melanocyte-Directed enzyme prodrug therapy (MDEPT): development of second generation prodrugs for targeted treatment of malignant melanoma. , 2001, Bioorganic & medicinal chemistry.

[176]  E. De Clercq,et al.  Synthesis and evaluation of novel amidate prodrugs of PMEA and PMPA. , 2001, Bioorganic & medicinal chemistry letters.

[177]  N. Rainov.  A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. , 2000, Human gene therapy.

[178]  H. Ishitsuka,et al.  The design and synthesis of a new tumor-selective fluoropyrimidine carbamate, capecitabine. , 2000, Bioorganic & medicinal chemistry.

[179]  V. Ganapathy,et al.  Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. , 2000, Journal of pharmaceutical sciences.

[180]  D. Cruz.  Midodrine: a selective α-adrenergic agonist for orthostatic hypotension and dialysis hypotension , 2000, Expert opinion on pharmacotherapy.

[181]  C. Koboldt,et al.  N-[[(5-methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: A potent and selective inhibitor of COX-2 for parenteral administration. , 2000, Journal of medicinal chemistry.

[182]  J. Metzger,et al.  Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs. , 2000, Journal of medicinal chemistry.

[183]  N. Bodor,et al.  Soft drug design: General principles and recent applications , 2000, Medicinal research reviews.

[184]  L. Murray,et al.  Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours , 1999, British Journal of Cancer.

[185]  A. Photiou,et al.  Melanocyte-directed enzyme prodrug therapy (MDEPT): development of a targeted treatment for malignant melanoma. , 1999, Bioorganic & medicinal chemistry.

[186]  Валентино Дж. Стелла,et al.  The water-soluble prodrugs of hindered alcohols or phenols , 1999 .

[187]  R. Cunha,et al.  Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives. , 1999, Journal of medicinal chemistry.

[188]  E. De Clercq,et al.  Synthesis, Anti-Human Immunodeficiency Virus Activity and Esterase Lability of Some Novel Carboxylic Ester-Modified Phosphoramidate Derivatives of Stavudine (d4T) , 1998, Antiviral chemistry & chemotherapy.

[189]  Stella,et al.  Some relationships between the physical properties of various 3-acyloxymethyl prodrugs of phenytoin to structure: potential in vivo performance implications , 1998, Journal of pharmaceutical sciences.

[190]  R. Blouin,et al.  Stability of Cephalosporin Prodrug Esters in Human Intestinal Juice: Implications for Oral Bioavailability , 1998, Antimicrobial Agents and Chemotherapy.

[191]  A. Guo,et al.  Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir. , 1998, Biochemical and biophysical research communications.

[192]  P. Workman,et al.  Reduction of the indoloquinone anticancer drug EO9 by purified DT-diaphorase: a detailed kinetic study and analysis of metabolites. , 1998, Biochemical pharmacology.

[193]  Browning Jm,et al.  Tirapazamine: laboratory data relevant to clinical activity. , 1998 .

[194]  H. Ishitsuka,et al.  Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. , 1998, European journal of cancer.

[195]  Chun Xing Li,et al.  Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate. , 1998, Cancer research.

[196]  E. De Clercq,et al.  Synthesis and Anti-HIV Activity of some Novel Chain-Extended Phosphoramidate Derivatives of d4T (Stavudine): Esterase Hydrolysis as a Rapid Predictive Test for Antiviral Potency , 1998, Antiviral chemistry & chemotherapy.

[197]  H. Ishitsuka,et al.  Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. , 1998, Biochemical pharmacology.

[198]  Norbert Bischofberger,et al.  Identification of GS 4104 as an Orally Bioavailable Prodrug of the Influenza Virus Neuraminidase Inhibitor GS 4071 , 1998, Antimicrobial Agents and Chemotherapy.

[199]  D. Sitar.  Clinical Pharmacokinetics of Bambuterol , 1996, Clinical pharmacokinetics.

[200]  H. Villar,et al.  Design, synthesis, and evaluation of latent alkylating agents activated by glutathione S-transferase. , 1996, Journal of medicinal chemistry.

[201]  L. Wiseman,et al.  Secnidazole , 1996, Drugs.

[202]  P. Rolan,et al.  Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans , 1995, Antimicrobial agents and chemotherapy.

[203]  H. Möllmann,et al.  Pharmacokinetic/Pharmacodynamic Evaluation of Deflazacort in Comparison to Methylprednisolone and Prednisolone , 1995, Pharmaceutical Research.

[204]  G. Ksander,et al.  Dicarboxylic acid dipeptide neutral endopeptidase inhibitors. , 1995, Journal of medicinal chemistry.

[205]  D. Jung,et al.  Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients. , 1995, Clinical therapeutics.

[206]  J. C. Martin,et al.  Synthesis, oral bioavailability determination, and in vitro evaluation of prodrugs of the antiviral agent 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA). , 1994, Journal of medicinal chemistry.

[207]  M. Lyttle,et al.  Glutathione-S-transferase activates novel alkylating agents. , 1994, Journal of medicinal chemistry.

[208]  J. C. Martin,et al.  Synthesis and in vitro evaluation of a phosphonate prodrug: bis(pivaloyloxymethyl) 9-(2-phosphonylmethoxyethyl)adenine. , 1992, Antiviral research.

[209]  K. Yamaguchi,et al.  Synthesis and antitumor activity of 20(S)-camptothecin derivatives: carbamate-linked, water-soluble derivatives of 7-ethyl-10-hydroxycamptothecin. , 1991, Chemical & pharmaceutical bulletin.

[210]  William A. Lee,et al.  Bioavailability Improvement of Mycophenolic Acid Through Amino Ester Derivatization , 1990, Pharmaceutical Research.

[211]  A. Tunek,et al.  Hydrolysis of 3H-bambuterol, a carbamate prodrug of terbutaline, in blood from humans and laboratory animals in vitro. , 1988, Biochemical pharmacology.

[212]  A. Tunek,et al.  Bambuterol, a carbamate ester prodrug of terbutaline, as inhibitor of cholinesterases in human blood. , 1988, Drug metabolism and disposition: the biological fate of chemicals.

[213]  M. Nishimura,et al.  KY-109, a new bifunctional prodrug of cephalosporin. II. Mechanism of oral absorption. , 1988, Chemical & pharmaceutical bulletin.

[214]  J. Nutt,et al.  Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients , 1986, Neurology.

[215]  M. Keating,et al.  Clinical pharmacology of polyethylene glycol-L-asparaginase. , 1986, Drug metabolism and disposition: the biological fate of chemicals.

[216]  H. Möllmann,et al.  Kinetics of methylprednisolone and its hemisuccinate ester , 1985, Clinical pharmacology and therapeutics.

[217]  W R Woodward,et al.  The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. , 1984, The New England journal of medicine.

[218]  W. Wargin,et al.  Pharmacokinetics of intravenous chloramphenicol sodium succinate in adult patients with normal renal and hepatic function , 1982, Journal of Pharmacokinetics and Biopharmaceutics.

[219]  J. Kopeček,et al.  Degradation of side-chains ofN-(2-hydroxypropyl)methacrylamide copolymers by lysosomal thiol-proteinases , 1982, Bioscience reports.

[220]  J. Aronson,et al.  The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man. , 1982, British journal of clinical pharmacology.

[221]  B. Baltzer,et al.  Mutual pro-drugs of beta-lactam antibiotics and beta-lactamase inhibitors. , 1980, The Journal of antibiotics.

[222]  ADRIEN ALBERT,et al.  Chemical Aspects of Selective Toxicity , 1958, Nature.

[223]  J. Najib,et al.  Pharmacologic and Pharmacokinetic Aspects Lisdexamfetamine dimesylate is a water-soluble prodrug of the single isomer—d-amphetamine and l-lysine—that remains Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder , 2017 .

[224]  Z. Temesgen,et al.  Isavuconazonium sulfate for the treatment of fungal infection. , 2016, Drugs of today.

[225]  A. Ray,et al.  Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus. , 2016, Antiviral research.

[226]  Mingnan Chen,et al.  Gene-Directed Enzyme Prodrug Therapy , 2014, The AAPS Journal.

[227]  S. Clas,et al.  Chemistry-enabled drug delivery (prodrugs): recent progress and challenges. , 2014, Drug discovery today.

[228]  M. Vicent,et al.  Polymer therapeutics-prospects for 21st century: the end of the beginning. , 2013, Advanced drug delivery reviews.

[229]  D. Grasela,et al.  Pharmaceutics, Drug Delivery and Pharmaceutical Technology Compartmental Absorption Modeling and Site of Absorption Studies to Determine Feasibility of an Extended-Release Formulation of an HIV-1 Attachment Inhibitor Phosphate Ester Prodrug , 2013 .

[230]  R. N. Brogden,et al.  Levodopa: A Review of its Pharmacological Properties and Therapeutic Uses with Particular Reference to Parkinsonism , 2012, Drugs.

[231]  K. Goa,et al.  Parecoxib (Parecoxib Sodium) , 2012, Drugs.

[232]  C. Perry,et al.  Gemtuzumab Ozogamicin , 2012, Drugs.

[233]  Monique P. Curran.  Bimatoprost , 2009, Drugs & aging.

[234]  J. Stangier.  Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate , 2008, Clinical pharmacokinetics.

[235]  Philip S Low,et al.  Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. , 2008, Accounts of chemical research.

[236]  Valentino J. Stella,et al.  Prodrugs : challenges and rewards , 2007 .

[237]  V. Stella,et al.  Prodrugs and Parenteral Drug Delivery , 2007 .

[238]  Tycho Heimbach,et al.  Overcoming Poor Aqueous Solubility of Drugs for Oral Delivery , 2007 .

[239]  M. Shelton,et al.  Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug. , 2006, Clinical pharmacokinetics.

[240]  Teruko Imai,et al.  Human carboxylesterase isozymes: catalytic properties and rational drug design. , 2006, Drug metabolism and pharmacokinetics.

[241]  E. Stone,et al.  Antitumor benzothiazoles. 26.(1) 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (GW 610, NSC 721648), a simple fluorinated 2-arylbenzothiazole, shows potent and selective inhibitory activity against lung, colon, and breast cancer cell lines. , 2006, Journal of medicinal chemistry.

[242]  William A. Lee,et al.  NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS, 20(4–7), 1091–1098 (2001) METABOLISM OF GS-7340, A NOVEL PHENYL MONOPHOSPHORAMIDATE INTRACELLULAR PRODRUG OF PMPA, IN BLOOD , 2003 .

[243]  D. Bjorkman,et al.  The efficacy of oral 5-ASAs in the treatment of active ulcerative colitis: a systematic review. , 2003, Reviews in gastroenterological disorders.

[244]  S. Shaffer,et al.  Poly-(L)-glutamic acid-paclitaxel (CT-2103) [XYOTAX], a biodegradable polymeric drug conjugate: characterization, preclinical pharmacology, and preliminary clinical data. , 2003, Advances in experimental medicine and biology.

[245]  G. Plosker,et al.  Adefovir dipivoxil: a review of its use in chronic hepatitis B. , 2003, Drugs.

[246]  A. Tolcher,et al.  A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[247]  K. Goa,et al.  Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer. , 2003, Drugs.

[248]  K. Blesch,et al.  Clinical Pharmacokinetics of Capecitabine , 2001, Clinical pharmacokinetics.

[249]  C. Perry,et al.  Oseltamivir , 2012, Drugs.

[250]  L. Murray,et al.  Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[251]  L. Wang,et al.  Tirapazamine: laboratory data relevant to clinical activity. , 1998, Anti-cancer drug design.

[252]  Sanjay S. Patel,et al.  Latanoprost , 1996 .

[253]  G. Persson,et al.  One month treatment with the once daily oral beta 2-agonist bambuterol in asthmatic patients. , 1995, The European respiratory journal.

[254]  G. Sachs,et al.  The pharmacology of the gastric acid pump: the H+,K+ ATPase. , 1995, Annual review of pharmacology and toxicology.

[255]  P. Lindberg,et al.  Chemical Reactions of Omeprazole and Omeprazole Analogues. I. A Survey of the Chemical Transformations of Omeprazole and its Analogues. , 1989 .

[256]  A. Tunek,et al.  The design and bioactivation of presystemically stable prodrugs. , 1988, Drug metabolism reviews.

[257]  B. Wallmark,et al.  Specific labelling of gastric H+,K+-ATPase by omeprazole. , 1988, Biochemical pharmacology.

[258]  P. de Miranda,et al.  Pharmacokinetics of acyclovir after intravenous and oral administration. , 1983, The Journal of antimicrobial chemotherapy.

[259]  J. Melby,et al.  Comparative studies on absorption and metabolic disposal of water-soluble corticosteroid esters. , 1961, Metabolism: clinical and experimental.